NeuroPace (NPCE) News Today $9.10 -0.09 (-0.98%) (As of 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NeuroPace FY2024 EPS Forecast Increased by Cantor FitzgeraldNovember 20 at 1:53 AM | americanbankingnews.comNeuroPace FY2024 EPS Forecast Raised by Cantor FitzgeraldNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of NeuroPace in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that tNovember 18 at 1:49 AM | marketbeat.comNeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy RatingNovember 15, 2024 | markets.businessinsider.comNeuroPace FY2024 EPS Estimate Boosted by Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for NeuroPace in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($1.03) forNovember 15, 2024 | marketbeat.comWells Fargo & Company Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock PriceNovember 15, 2024 | americanbankingnews.comNeuroPace price target lowered to $13 from $15 at Wells FargoNovember 13, 2024 | markets.businessinsider.comNeuroPace’s Strong Financial Performance and Strategic Advancements Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comNeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comNeuroPace raises FY24 revenue view to $78M-$80M from $76M-$78MNovember 13, 2024 | markets.businessinsider.comNeuroPace, Inc. Reports Strong Q3 2024 ResultsNovember 13, 2024 | markets.businessinsider.comNeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...November 13, 2024 | finance.yahoo.comNeuroPace, Inc. (NPCE) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 ResultNovember 11, 2024 | finance.yahoo.comNeuroPace submits safety, effectiveness data from RNS System study to FDANovember 6, 2024 | markets.businessinsider.comNeuroPace (NPCE) Scheduled to Post Quarterly Earnings on TuesdayNeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638401)November 5, 2024 | marketbeat.comNeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal EpilepsyNovember 4, 2024 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from AnalystsShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a bOctober 31, 2024 | marketbeat.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 223,991 Shares of StockOctober 29, 2024 | insidertrades.comLtd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 223,991 shares of NeuroPace stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the sale, the insider now directly owns 5,270,845 shares in the company, valued at $28,726,105.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.October 28, 2024 | marketbeat.comKCK LTD.'s Strategic Reduction in NeuroPace Inc SharesOctober 24, 2024 | finance.yahoo.comLtd. Kck Sells 3,720 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOctober 23, 2024 | insidertrades.comNeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024October 22, 2024 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 3,720 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 3,720 shares of the firm's stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $6.10, for a total value of $22,692.00. Following the completion of the transaction, the insider now owns 5,499,065 shares of the company's stock, valued at approximately $33,544,296.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.October 22, 2024 | marketbeat.comLtd. Kck Sells 2,572 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOctober 19, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 2,572 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 2,572 shares of the business's stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $6.35, for a total value of $16,332.20. Following the completion of the sale, the insider now owns 5,525,905 shares in the company, valued at approximately $35,089,496.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.October 18, 2024 | marketbeat.comNeuroPace Continues to Strengthen Management TeamOctober 16, 2024 | globenewswire.comMillennium Management LLC Acquires 80,324 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Millennium Management LLC boosted its holdings in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 13.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 686,037 shares of the company's stock after purchasing an additioOctober 12, 2024 | marketbeat.comKCK LTD. Reduces Stake in NeuroPace IncOctober 3, 2024 | finance.yahoo.comNantahala Capital Management LLC Has $4.66 Million Position in NeuroPace, Inc. (NASDAQ:NPCE)Nantahala Capital Management LLC lessened its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 20.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 616,823 shares of the company's stock after selling 161,437 shares during the period. NantOctober 1, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buySeptember 11, 2024 | marketbeat.comNeuroPace (NPCE) Gets a Buy from Lake StreetSeptember 5, 2024 | markets.businessinsider.comNeuroPace Strengthens Management Team with Two Key AppointmentsSeptember 4, 2024 | globenewswire.comNeuroPace Announces Participation at Two Upcoming Healthcare Investor ConferencesAugust 27, 2024 | globenewswire.comNeuroPace to Participate in Upcoming Healthcare Conferences in SeptemberAugust 22, 2024 | globenewswire.comNeuroPace: Only For Those With Strong NervesAugust 20, 2024 | seekingalpha.comResearch Analysts Set Expectations for NeuroPace, Inc.'s FY2024 Earnings (NASDAQ:NPCE)NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of NeuroPace in a research report issued on Wednesday, August 14th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of (August 19, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Position Raised by Vanguard Group Inc.Vanguard Group Inc. boosted its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 18.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 488,618 shares of the company's stock after purchasing an additional 75,51August 17, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation toAugust 17, 2024 | marketbeat.comNeuroPace: Strong Q2 Performance and Promising Future Drive ‘Outperform’ RatingAugust 16, 2024 | markets.businessinsider.comEarnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57August 16, 2024 | finance.yahoo.comQ3 2024 Earnings Estimate for NeuroPace, Inc. (NASDAQ:NPCE) Issued By Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for NeuroPace in a research report issued on Tuesday, August 13th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per shaAugust 16, 2024 | marketbeat.comNeuroPace, Inc.: NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 15, 2024 | finanznachrichten.deNeuroPace (NASDAQ:NPCE) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPSNeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The business's revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.36) EPS.August 14, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for NeuroPace (NASDAQ:NPCE)Cantor Fitzgerald reissued an "overweight" rating and issued a $18.00 target price on shares of NeuroPace in a research report on Wednesday.August 14, 2024 | marketbeat.comNeuroPace (NASDAQ:NPCE) PT Lowered to $15.00Wells Fargo & Company reduced their price target on NeuroPace from $20.00 to $15.00 and set an "overweight" rating on the stock in a research report on Wednesday.August 14, 2024 | marketbeat.comNeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 14, 2024 | finance.yahoo.comNeuroPace earnings: here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comNeuroPace (NPCE) to Release Quarterly Earnings on TuesdayNeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, August 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=611719)August 6, 2024 | marketbeat.comNeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024July 23, 2024 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Decrease in Short InterestNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 74,200 shares, a decline of 40.9% from the May 15th total of 125,500 shares. Based on an average daily volume of 114,000 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's shares are short sold.June 13, 2024 | marketbeat.com Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.850.46▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼112▲NPCE Articles Average Week Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Utah Medical Products News TELA Bio News Beyond Air News PAVmed News Pulse Biosciences News Bioventus News CeriBell News National Vision News Paragon 28 News Liquidia News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
